BACKGROUND: Intraprostatic PSMA targeted prodrugs/protoxins are under development in our laboratory. Future toxicologic studies of these therapies require identification of animal models that express PSMA within the prostate. METHOD: PSMA enzymatic activity and protein expression was determined. PSMA expression in the prostates of mouse, dog, and monkey were compared to humans by real-time PCR analysis. RESULTS: No substrate hydrolysis was observed in dog or monkey prostate homogenates. Monkey prostate was negative for PSMA protein expression. No significant PSMA mRNA levels were detected by real time PCR in mouse, dog, or monkey prostate tissue compared to PSMA negative tissues. CONCLUSIONS: PSMA is not expressed in any significant amount in the prostates of mouse, beagle dog, or macaque monkeys in this study but is expressed in high levels by human prostate. These non-human species, therefore, are not suitable toxicologic models to assess prostate damage from PSMA-activated intraprostatic prodrug/protoxin therapies. Copyright 2006 Wiley-Liss, Inc.
BACKGROUND: Intraprostatic PSMA targeted prodrugs/protoxins are under development in our laboratory. Future toxicologic studies of these therapies require identification of animal models that express PSMA within the prostate. METHOD:PSMA enzymatic activity and protein expression was determined. PSMA expression in the prostates of mouse, dog, and monkey were compared to humans by real-time PCR analysis. RESULTS: No substrate hydrolysis was observed in dog or monkey prostate homogenates. Monkey prostate was negative for PSMA protein expression. No significant PSMA mRNA levels were detected by real time PCR in mouse, dog, or monkey prostate tissue compared to PSMA negative tissues. CONCLUSIONS:PSMA is not expressed in any significant amount in the prostates of mouse, beagle dog, or macaque monkeys in this study but is expressed in high levels by human prostate. These non-human species, therefore, are not suitable toxicologic models to assess prostate damage from PSMA-activated intraprostatic prodrug/protoxin therapies. Copyright 2006 Wiley-Liss, Inc.
Authors: Xiaoxi Ling; Joseph D Latoche; Cindy J Choy; Brenda F Kurland; Charles M Laymon; Yijen Wu; Nathan Salamacha; Ding Shen; Jonathan J Geruntho; Lora H Rigatti; Hillarie P Windish; Beatrice Langton-Webster; Clifford E Berkman; Carolyn J Anderson Journal: Mol Imaging Biol Date: 2020-04 Impact factor: 3.488
Authors: Tanushree Ganguly; Shorouk Dannoon; Mark R Hopkins; Stephanie Murphy; Hendry Cahaya; Joseph E Blecha; Salma Jivan; Christopher R Drake; Cyril Barinka; Ella F Jones; Henry F VanBrocklin; Clifford E Berkman Journal: Nucl Med Biol Date: 2015-06-09 Impact factor: 2.408
Authors: Shawn M Hillier; Kevin P Maresca; Frank J Femia; John C Marquis; Catherine A Foss; Nghi Nguyen; Craig N Zimmerman; John A Barrett; William C Eckelman; Martin G Pomper; John L Joyal; John W Babich Journal: Cancer Res Date: 2009-08-25 Impact factor: 12.701
Authors: Suzanne E Lapi; Hilla Wahnishe; David Pham; Lisa Y Wu; Jessie R Nedrow-Byers; Tiancheng Liu; Kaveh Vejdani; Henry F VanBrocklin; Clifford E Berkman; Ella F Jones Journal: J Nucl Med Date: 2009-11-12 Impact factor: 10.057
Authors: Jessie R Nedrow; Joseph D Latoche; Kathryn E Day; Jalpa Modi; Tanushree Ganguly; Dexing Zeng; Brenda F Kurland; Clifford E Berkman; Carolyn J Anderson Journal: Mol Imaging Biol Date: 2016-06 Impact factor: 3.488
Authors: Sung Chang Lee; Jennifer S Y Ma; Min Soo Kim; Eduardo Laborda; Sei-Hyun Choi; Eric N Hampton; Hwayoung Yun; Vanessa Nunez; Michelle T Muldong; Christina N Wu; Wenxue Ma; Anna A Kulidjian; Christopher J Kane; Vadim Klyushnichenko; Ashley K Woods; Sean B Joseph; Mike Petrassi; John Wisler; Jing Li; Christina A M Jamieson; Peter G Schultz; Chan Hyuk Kim; Travis S Young Journal: Sci Adv Date: 2021-08-11 Impact factor: 14.136